Biovica records SEK 2.6m in total net sales (51% above Q1 last year), and clinical sales increased by 72%. Biovica is working together with the US partner Tempus, and the next stage is to roll out DiviTum over the coming quarters. Bioivca delivers high growth from a very modest base, and the challenge for the rest of 2025/26 is to provide a significant absolute increase, allowing Bioivca to progress towards break-even the following year.
LÄS MER
